Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

Journal of Clinical Oncology

Volumn 24, Issue 1, 2006, Pages 166-173

  O'Connor, Owen A ^a   Heaney, Mark L ^a   Schwartz, Lawrence ^a   Richardson, Stacie ^a   Willim, Robert ^a   MacGregor Cortelli, Barbara ^a   Curly, Tracey ^a   Moskowitz, Craig ^a   Portlock, Carol ^a   Horwitz, Steven ^a   Zelenetz, Andrew D ^a   Frankel, Stanley ^a   Richon, Victoria ^a   Marks, Paul ^a   Kelly, William K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; VORINOSTAT; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; HISTONE DEACETYLASE; HYDROXAMIC ACID;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; CANCER FATIGUE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG FORMULATION; DRUG RESPONSE; FEMALE; FEVER; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; INFORMED CONSENT; KIDNEY FUNCTION; LARGE CELL LYMPHOMA; LIVER FUNCTION; LYMPHATIC LEUKEMIA; MALE; MANTLE CELL LYMPHOMA; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOID LEUKEMIA; NEUTROPHIL COUNT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; SEPSIS; SOLID TUMOR; T CELL LYMPHOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; BLOOD DISEASE; DRUG ANTAGONISM; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FEMALE; HEMATOLOGIC NEOPLASMS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 33644836549     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.9679     Document Type: Article

References (17)

1. Warrell RP Jr, He LZ, Richon V, et al: Therapeutic targeting of transcription in acute promyelocyte leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90:1621-1625, 1998
2. Pasqualucci L, Migliazza A, Basso K, et al: Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphoma. Blood 101:2914-2923, 2003
3. Shaffer AL, Yu X, He Y, et al: BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 13: 199-212, 2000
4. Baron BW, Anastasi J, Thirman MJ, et al: The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: Implications for a role of BCL6 in the down-regulation of apoptosis. Proc Natl Acad Sci U S A 99:2860-2865, 2002
5. Bereshchenko OR, Gu W, Dalla-Favera R: Acetylation inactivates the transcriptional repressor BCL6. Nat Genet 32:606-613, 2002
6. Marks PA, Richon VM, Rifkind RA: Histone deacetylase inhibitors: Inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst 92:1210-1216, 2000
7. Marks P, Rifkind RA, Richon VM, et al: Histone deacetylases and cancer: Causes and therapies. Nat Rev Cancer 1:194-202, 2001
8. Richon VM, Emiliani S, Verdin E, et al: A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci U S A 95:3003-3007, 1998
9. Butler LM, Agus DB, Scher HI, et al: Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170, 2000
10. Finnin MS, Donigian JR, Cohen A, et al: Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188-193, 1999
11. Kelly WK, Richon VM, O'Connor O, et al: Phase I clinical trial of histone deacetylase inhibitor: Suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res 9:3578-3588, 2003
12. Kelly WK, O'Connor OA, Krug L, et al: Phase I study of the oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 23:3923-3931, 2005
13. Cheson BD, Horning SJ, Coiffier B, et al: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas: NCI Sponsored International Working Group. J Clin Oncol 17:1244, 1999
14. Cheson BD, Bennett JM, Grever M, et al: National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment. Blood 87:4990-4997, 1996
15. Piekarz RL, Robey R, Sandor V, et al: Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: A case report. Blood 98:2865-2868, 2001
16. Turner J, Wright J, Leonard S, et al: Responses and molecular markers in patients with peripheral T-cell lymphoma treated on a phase II trial of depsipeptide, FK228. Am Soc Clin Oncol 23:16s, 2005 (abstr 3061)
17. Talpur C, Zhang A, Goy V, et al: Phase II trial of oral suberoylanilide hydroxamic acid (SAHA) for cutaneous T-cell lymphoma (CTCL) unresponsive to conventional therapy. Am Soc Clin Oncol 23:577s, 2005 (abstr 6571)